Cargando…

Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

BACKGROUND: Adverse drug events are unintended and harmful events related to medications. Adverse drug events are important for patient care, quality improvement, drug safety research, and postmarketing surveillance, but they are vastly underreported. OBJECTIVE: Our objectives were to identify barri...

Descripción completa

Detalles Bibliográficos
Autores principales: Hohl, Corinne M, Small, Serena S, Peddie, David, Badke, Katherin, Bailey, Chantelle, Balka, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849794/
https://www.ncbi.nlm.nih.gov/pubmed/29487041
http://dx.doi.org/10.2196/publichealth.9282
_version_ 1783306105655394304
author Hohl, Corinne M
Small, Serena S
Peddie, David
Badke, Katherin
Bailey, Chantelle
Balka, Ellen
author_facet Hohl, Corinne M
Small, Serena S
Peddie, David
Badke, Katherin
Bailey, Chantelle
Balka, Ellen
author_sort Hohl, Corinne M
collection PubMed
description BACKGROUND: Adverse drug events are unintended and harmful events related to medications. Adverse drug events are important for patient care, quality improvement, drug safety research, and postmarketing surveillance, but they are vastly underreported. OBJECTIVE: Our objectives were to identify barriers to adverse drug event documentation and factors contributing to underreporting. METHODS: This qualitative study was conducted in 1 ambulatory center, and the emergency departments and inpatient wards of 3 acute care hospitals in British Columbia between March 2014 and December 2016. We completed workplace observations and focus groups with general practitioners, hospitalists, emergency physicians, and hospital and community pharmacists. We analyzed field notes by coding and iteratively analyzing our data to identify emerging concepts, generate thematic and event summaries, and create workflow diagrams. Clinicians validated emerging concepts by applying them to cases from their clinical practice. RESULTS: We completed 238 hours of observations during which clinicians investigated 65 suspect adverse drug events. The observed events were often complex and diagnosed over time, requiring the input of multiple providers. Providers documented adverse drug events in charts to support continuity of care but never reported them to external agencies. Providers faced time constraints, and reporting would have required duplication of documentation. CONCLUSIONS: Existing reporting systems are not suited to capture the complex nature of adverse drug events or adapted to workflow and are simply not used by frontline clinicians. Systems that are integrated into electronic medical records, make use of existing data to avoid duplication of documentation, and generate alerts to improve safety may address the shortcomings of existing systems and generate robust adverse drug event data as a by-product of safer care.
format Online
Article
Text
id pubmed-5849794
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-58497942018-03-19 Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study Hohl, Corinne M Small, Serena S Peddie, David Badke, Katherin Bailey, Chantelle Balka, Ellen JMIR Public Health Surveill Original Paper BACKGROUND: Adverse drug events are unintended and harmful events related to medications. Adverse drug events are important for patient care, quality improvement, drug safety research, and postmarketing surveillance, but they are vastly underreported. OBJECTIVE: Our objectives were to identify barriers to adverse drug event documentation and factors contributing to underreporting. METHODS: This qualitative study was conducted in 1 ambulatory center, and the emergency departments and inpatient wards of 3 acute care hospitals in British Columbia between March 2014 and December 2016. We completed workplace observations and focus groups with general practitioners, hospitalists, emergency physicians, and hospital and community pharmacists. We analyzed field notes by coding and iteratively analyzing our data to identify emerging concepts, generate thematic and event summaries, and create workflow diagrams. Clinicians validated emerging concepts by applying them to cases from their clinical practice. RESULTS: We completed 238 hours of observations during which clinicians investigated 65 suspect adverse drug events. The observed events were often complex and diagnosed over time, requiring the input of multiple providers. Providers documented adverse drug events in charts to support continuity of care but never reported them to external agencies. Providers faced time constraints, and reporting would have required duplication of documentation. CONCLUSIONS: Existing reporting systems are not suited to capture the complex nature of adverse drug events or adapted to workflow and are simply not used by frontline clinicians. Systems that are integrated into electronic medical records, make use of existing data to avoid duplication of documentation, and generate alerts to improve safety may address the shortcomings of existing systems and generate robust adverse drug event data as a by-product of safer care. JMIR Publications 2018-02-27 /pmc/articles/PMC5849794/ /pubmed/29487041 http://dx.doi.org/10.2196/publichealth.9282 Text en ©Corinne M Hohl, Serena S Small, David Peddie, Katherin Badke, Chantelle Bailey, Ellen Balka. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 27.02.2018. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on http://publichealth.jmir.org, as well as this copyright and license information must be included.
spellingShingle Original Paper
Hohl, Corinne M
Small, Serena S
Peddie, David
Badke, Katherin
Bailey, Chantelle
Balka, Ellen
Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study
title Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study
title_full Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study
title_fullStr Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study
title_full_unstemmed Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study
title_short Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study
title_sort why clinicians don’t report adverse drug events: qualitative study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849794/
https://www.ncbi.nlm.nih.gov/pubmed/29487041
http://dx.doi.org/10.2196/publichealth.9282
work_keys_str_mv AT hohlcorinnem whycliniciansdontreportadversedrugeventsqualitativestudy
AT smallserenas whycliniciansdontreportadversedrugeventsqualitativestudy
AT peddiedavid whycliniciansdontreportadversedrugeventsqualitativestudy
AT badkekatherin whycliniciansdontreportadversedrugeventsqualitativestudy
AT baileychantelle whycliniciansdontreportadversedrugeventsqualitativestudy
AT balkaellen whycliniciansdontreportadversedrugeventsqualitativestudy